Entrada Therapeutics Inc (TRDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $199.28M
Last updated: Nov 17, 2026 at 11:05 AM ET
Entrada Therapeutics Inc (TRDA) Financials: Revenue, Profit and Cash Flow
Entrada Therapeutics reported revenue of $25.42M for the fiscal year ended Dec 31, 2025, down 87.9% from the year before. That year, net income was -$143.75M with a net margin of -565.5%, operating cash flow was -$128.51M and free cash flow was -$129.55M. The quarter ended Sep 30, 2026 had revenue of $905.00K and net income of -$39.74M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $25.42M | -87.9% | 100.0% | -621.1% | -565.5% |
| Dec 2024 | $210.78M | +63.4% | 100.0% | 22.3% | 31.1% |
| Dec 2023 | $129.01M | N/A | 100.0% | -2.5% | -5.2% |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $25.42M | $210.78M | $129.01M | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $104.00K |
| Gross profit | $25.42M | $210.78M | $129.01M | $0 | $0 | $0 | -$104.00K |
| Research and development | $142.27M | $125.31M | $99.88M | $66.61M | $35.93M | $21.10M | $8.22M |
| Operating income | -$157.90M | $47.01M | -$3.16M | -$97.25M | -$51.13M | -$26.67M | -$11.82M |
| Net income | -$143.75M | $65.63M | -$6.68M | -$94.62M | -$51.16M | -$26.52M | -$4.65M |
| EBITDA | -$157.47M | N/A | $9.12M | -$92.57M | -$50.04M | -$26.20M | -$11.72M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $905.00K | $898.00K | $875.00K | $1.30M | $1.61M | $1.95M | $20.56M | $37.40M | $19.57M | $94.69M | $59.12M | $41.85M |
| Gross profit | $905.00K | $898.00K | $875.00K | $1.30M | $1.61M | $1.95M | $20.56M | $37.40M | $19.57M | $94.69M | $59.12M | $41.85M |
| Operating income | -$41.69M | -$44.96M | -$42.30M | -$42.21M | -$47.05M | -$46.85M | -$21.79M | -$5.87M | -$21.66M | $53.42M | $21.11M | $4.91M |
| Net income | -$39.74M | -$42.76M | -$39.72M | -$39.16M | -$44.13M | -$43.10M | -$17.35M | $1.13M | -$14.03M | $55.03M | $23.50M | -$9.54M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $4.14M by $86.26M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $377.38M | $526.32M | $469.19M | $252.06M | $305.83M | $43.53M | $18.24M |
| Current assets | $306.25M | $440.04M | $369.77M | $209.88M | $298.70M | $39.95M | $17.44M |
| Cash and equivalents | $90.39M | $101.21M | $67.60M | $45.16M | $291.06M | $39.05M | $16.84M |
| Total liabilities | $71.25M | $97.64M | $226.83M | $39.50M | $7.12M | $3.36M | $33.76M |
| Short-term debt | $4.14M | $7.56M | $7.91M | $8.41M | N/A | N/A | N/A |
| Shareholder equity | $306.13M | $428.68M | $242.36M | $212.55M | $298.72M | -$41.49M | -$15.52M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $266.88M | $298.88M | $335.52M | $377.38M | $412.90M | $448.78M | $486.48M | $526.32M | $554.59M | $581.96M | $510.84M | $469.19M |
| Total liabilities | $68.56M | $65.47M | $64.66M | $71.25M | $72.18M | $69.28M | $69.22M | $97.64M | $132.14M | $152.04M | $241.48M | $226.83M |
| Cash and equivalents | $112.24M | $99.28M | $76.44M | $90.39M | $93.29M | $72.48M | $67.84M | $101.21M | $78.05M | $185.25M | $68.44M | $67.60M |
| Shareholder equity | $198.32M | $233.41M | $270.85M | $306.13M | $340.72M | $379.50M | $417.26M | $428.68M | $422.45M | $429.93M | $269.37M | $242.36M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$128.51M | -$41.56M | $139.80M | -$93.79M | -$50.86M | -$25.57M | -$10.80M |
| Capital expenditures | $1.04M | $3.16M | $5.61M | $2.89M | $4.58M | $2.32M | $630.00K |
| Free cash flow | -$129.55M | -$44.72M | $134.19M | -$96.67M | -$55.44M | -$27.89M | -$11.43M |
| Investing cash flow | $116.81M | -$27.80M | -$138.40M | -$148.65M | -$4.58M | -$2.32M | -$630.00K |
| Financing cash flow | $887.00K | $102.96M | $21.04M | $479.00K | $307.46M | $50.09M | $38.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.96M | -$32.46M | -$41.70M | -$32.20M | -$28.31M | -$29.49M | -$38.51M | -$31.61M | -$24.27M | $39.83M | -$25.52M | -$4.01M |
| Capital expenditures | $161.00K | $11.00K | $44.00K | $207.00K | $171.00K | $275.00K | $1.14M | $635.00K | $639.00K | $1.05M | $838.00K | $976.00K |
| Free cash flow | -$30.13M | -$32.47M | -$41.74M | -$32.41M | -$28.48M | -$29.76M | -$39.65M | -$32.24M | -$24.91M | $38.79M | -$26.36M | -$4.99M |
Frequently Asked Questions About TRDA
What is Entrada Therapeutics' annual revenue?
Entrada Therapeutics reported revenue of $25.42M for the fiscal year ended Dec 31, 2025.
How fast is Entrada Therapeutics' revenue growing?
Revenue was down 87.9% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Entrada Therapeutics profitable?
No. Entrada Therapeutics reported net income of -$143.75M for the fiscal year ended Dec 31, 2025, with a net margin of -565.5%.
How much free cash flow does TRDA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$128.51M minus capital expenditures of $1.04M produced free cash flow of -$129.55M.
How much debt does Entrada Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $4.14M and cash and equivalents of $90.39M.
TRDA pages: Overview, Earnings, Forecast, Financials, Competitors